Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
LY011
i
Other names:
LY011, LY 011, LY-011
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
China Biotech Services
Drug class:
CLDN18.2-targeted CAR-T immunotherapy
Related drugs:
‹
CT041 (4)
IBI-345 (3)
AZD6422 (0)
CT048 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HEC-016 (0)
IM92 (0)
IMC002 (0)
IMC008 (0)
KD-182 (0)
KD-496 (0)
LB1908 (0)
XKDCT086 (0)
anti-Claudin 18.2 CAR-T cell therapy (0)
CT041 (4)
IBI-345 (3)
AZD6422 (0)
CT048 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HEC-016 (0)
IM92 (0)
IMC002 (0)
IMC008 (0)
KD-182 (0)
KD-496 (0)
LB1908 (0)
XKDCT086 (0)
anti-Claudin 18.2 CAR-T cell therapy (0)
›
Associations
News
Trials
Filter by
Latest
over3years
A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma (clinicaltrials.gov)
P1, N=18, Recruiting, Shanghai Longyao Biotechnology Inc., Ltd.
over 3 years ago
New P1 trial
|
CLDN18 (Claudin 18)
|
LY011
over3years
Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov)
P1, N=30, Recruiting, Shanghai Longyao Biotechnology Inc., Ltd.
over 3 years ago
Clinical • New P1 trial • CAR T-Cell Therapy
|
CLDN18 (Claudin 18)
|
LY011
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login